These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8670319)

  • 1. Protein metabolism in rheumatoid arthritis and aging. Effects of muscle strength training and tumor necrosis factor alpha.
    Rall LC; Rosen CJ; Dolnikowski G; Hartman WJ; Lundgren N; Abad LW; Dinarello CA; Roubenoff R
    Arthritis Rheum; 1996 Jul; 39(7):1115-24. PubMed ID: 8670319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preserved skeletal muscle protein anabolic response to acute exercise and protein intake in well-treated rheumatoid arthritis patients.
    Mikkelsen UR; Dideriksen K; Andersen MB; Boesen A; Malmgaard-Clausen NM; Sørensen IJ; Schjerling P; Kjær M; Holm L
    Arthritis Res Ther; 2015 Sep; 17():271. PubMed ID: 26407995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis.
    Seriolo B; Paolino S; Sulli A; Fasciolo D; Cutolo M
    Ann N Y Acad Sci; 2006 Jun; 1069():414-9. PubMed ID: 16855168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
    Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
    J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis.
    Seriolo B; Paolino S; Sulli A; Ferretti V; Cutolo M
    Ann N Y Acad Sci; 2006 Jun; 1069():420-7. PubMed ID: 16855169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.
    Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W
    Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease activity improvement in rheumatoid arthritis treated with tumor necrosis factor-α inhibitors correlates with increased soluble Fas levels.
    Romano E; Terenzi R; Manetti M; Peruzzi F; Fiori G; Nacci F; Bellando-Randone S; Matucci-Cerinic M; Guiducci S
    J Rheumatol; 2014 Oct; 41(10):1961-5. PubMed ID: 25179850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate.
    Varani K; Massara A; Vincenzi F; Tosi A; Padovan M; Trotta F; Borea PA
    Arthritis Rheum; 2009 Oct; 60(10):2880-91. PubMed ID: 19790066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.
    Kapetanovic MC; Roseman C; Jönsson G; Truedsson L; Saxne T; Geborek P
    Arthritis Rheum; 2011 Dec; 63(12):3723-32. PubMed ID: 21834061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis.
    Steiner G; Studnicka-Benke A; Witzmann G; Höfler E; Smolen J
    J Rheumatol; 1995 Mar; 22(3):406-12. PubMed ID: 7783054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis.
    Ingegnoli F; Fantini F; Griffini S; Soldi A; Meroni PL; Cugno M
    Clin Exp Rheumatol; 2010; 28(2):254-7. PubMed ID: 20483049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M; Zwicker M; Villiger PM
    J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor.
    Hjeltnes G; Hollan I; Førre O; Wiik A; Lyberg T; Mikkelsen K; Agewall S
    Clin Exp Rheumatol; 2013; 31(3):415-21. PubMed ID: 23465067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia.
    Metsios GS; Stavropoulos-Kalinoglou A; Douglas KM; Koutedakis Y; Nevill AM; Panoulas VF; Kita M; Kitas GD
    Rheumatology (Oxford); 2007 Dec; 46(12):1824-7. PubMed ID: 18032540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy.
    Mäki-Petäjä KM; Hall FC; Booth AD; Wallace SM; Yasmin ; Bearcroft PW; Harish S; Furlong A; McEniery CM; Brown J; Wilkinson IB
    Circulation; 2006 Sep; 114(11):1185-92. PubMed ID: 16952987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis.
    Macías I; García-Pérez S; Ruiz-Tudela M; Medina F; Chozas N; Girón-González JA
    J Rheumatol; 2005 Nov; 32(11):2102-8. PubMed ID: 16265686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relations of serum COMP to cardiovascular risk factors and endothelial function in patients with rheumatoid arthritis treated with methotrexate and TNF-α inhibitors.
    Hjeltnes G; Hollan I; Førre Ø; Wiik A; Lyberg T; Mikkelsen K; Agewall S
    J Rheumatol; 2012 Jul; 39(7):1341-7. PubMed ID: 22660798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of 24 months of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study.
    Sfriso P; Caso F; Filardo GS; Botsios C; Costa L; Scarpa R; Todesco S; Spinella P; Oliviero F; Punzi L
    Clin Rheumatol; 2016 Jun; 35(6):1615-8. PubMed ID: 27048267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.
    Barrera P; van der Maas A; van Ede AE; Kiemeney BA; Laan RF; van de Putte LB; van Riel PL
    Rheumatology (Oxford); 2002 Apr; 41(4):430-9. PubMed ID: 11961174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.